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Abstract
Background: Glioma is the most common and primary brain tumors in adults. Despite the available multimodal
therapies, glioma patients appear to have a poor prognosis. The Hedgehog (Hh) signaling is involved in
tumorigenesis and emerged as a promising target for brain tumors. Glabrescione B (GlaB) has been recently
identified as the first direct inhibitor of Gli1, the downstream effector of the pathway.
Methods: We established the overexpression of Gli1 in murine glioma cells (GL261) and GlaB effect on cell viability.
We used 1H-nuclear magnetic resonance (NMR) metabolomic approach to obtain informative metabolic snapshots
of GL261 cells acquired at different time points during GlaB treatment. The activation of AMP activated protein
Kinase (AMPK) induced by GlaB was established by western blot. After the orthotopic GL261 cells injection in the
right striatum of C57BL6 mice and the intranasal (IN) GlaB/mPEG5kDa-Cholane treatment, the tumor growth was
evaluated. The High Performance Liquid Chromatography (HPLC) combined with Mass Spectrometry (MS) was used
to quantify GlaB in brain extracts of treated mice.
Results: We found that GlaB affected the growth of murine glioma cells both in vitro and in vivo animal model.
Using an untargeted 1H-NMR metabolomic approach, we found that GlaB stimulated the glycolytic metabolism in
glioma, increasing lactate production. The high glycolytic rate could in part support the cytotoxic effects of GlaB,
since the simultaneous blockade of lactate efflux with α-cyano-4-hydroxycinnamic acid (ACCA) affected glioma cell
growth. According to the metabolomic data, we found that GlaB increased the phosphorylation of AMPK, a cellular
energy sensor involved in the anabolic-to-catabolic transition.
Conclusions: Our results indicate that GlaB inhibits glioma cell growth and exacerbates Warburg effect, increasing
lactate production. In addition, the simultaneous blockade of Gli1 and lactate efflux amplifies the anti-tumor effect
in vivo, providing new potential therapeutic strategy for this brain tumor.
Keywords: Glioma, Hh pathway, Isoflavones, 1H-NMR spectroscopy, Metabolomics
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: deborah.quaglio@uniroma1.it
†Giuseppina D’Alessandro, Deborah Quaglio, Veronica Ghini and Cristina
Limatola contributed equally to this work.
3Department of Chemistry and Technology of Drugs, “Department of
Excellence 2018−2022”, Sapienza University of Rome, P.le Aldo Moro 5, 00185
Rome, Italy
Full list of author information is available at the end of the article
D’Alessandro et al. Cell Communication and Signaling          (2019) 17:108 
https://doi.org/10.1186/s12964-019-0421-8
Background
Glioblastoma (GBM) is the most frequent and lethal
cancer originating in the central nervous system (CNS)
in adults [1, 2]. Despite current treatments consisting of
surgery followed by adjuvant radiotherapy and chemo-
therapy, GBM patients have a mean survival of 15
months from diagnosis [3]. Even if significant progresses
in molecular targeting of brain tumors were made,
several promising preclinical results revealed poor trans-
latability, and there is urgent need of novel targeted
therapies for patients. The Hedgehog (Hh) signaling
pathway is involved in many physiological and patho-
logical processes, including cancer, adipocyte differenti-
ation, diabetes and obesity [4, 5]. In particular, the Hh
signaling is implicated in tissue-patterning during em-
bryonic development, in tissues repair and in epithelial-
to-mesenchymal transition [6, 7]. The binding of Hh
ligands (Sonic hedgehog (Shh), Indian hedgehog (Ihh),
or Desert hedgehog (Dhh)) releases the inhibitory effect
of Patched (Ptch), a transmembrane receptor, on
Smoothened (Smo), which is also located on cell mem-
brane [8]. The signaling cascade initiated by Smo leads
to the activation and nuclear localization of the tran-
scription factors of the zinc finger family Gli (Gli1, Gli2
and Gli3), which drive the expression of Hh target genes,
mostly involved in proliferation, survival, and angiogen-
esis [9]. Alterations of the Hh-pathway contribute to
tumorigenesis and tumor growth of several human can-
cers, including medulloblastoma [10], rhabdomyosar-
coma [11], melanoma [12], basal cell carcinoma [13],
and glioma [14], through several mechanisms. Although
the role of Hh in the infiltrative growth of glioma re-
mains to be elucidated, several studies claim its involve-
ment in the promotion of cell proliferation, cancer stem
cell self-renewal and tumor progression [15–17]. Thus,
this pathway already emerged as a therapeutic target in
oncology [18–20] and we have recently identified the
first natural small molecule able to interfere with Gli
activity [19], Glabrescione B (GlaB). In particular, GlaB
binds to Gli1, and impairs its activity interfering with
DNA interaction [19].
It is known that several malignant tumors, including
GBM, consume high amounts of glucose at fast rate, with
the production of lactic acid, even in the presence of oxy-
gen (“Warburg effect”) [21–23]. To promote the high
exploitation of glucose for rapid energy production
through glycolytic flux and to avoid intracellular acidosis,
cancer cells rapidly wipe out the lactic acid to the extracel-
lular environment by the plasma membrane mono-carb-
oxylate transporters (MCTs) [24]. Considering that lactate
is a key metabolic driver implicated in the regulation of
metabolic pathways, immune responses and cell-to-cell
communication within the tumor microenvironment,
targeting lactate metabolism and transport can represent a
promising approach to counteract cancer growth and pro-
gression [25–27]. In this study, we found that GlaB treat-
ment of GL261 glioma cells inhibits Gli1 transcription,
reducing glioma cell growth. Using an untargeted 1H-
NMR metabolomic approach [28, 29], we also demon-
strated that GlaB treatment increases both intra- and
extracellular levels of lactate in GL261 cells, promoting
the glycolytic process over the tricarboxylic acid cycle
(TCA). Consistently, GlaB treatment induces the phos-
phorylation of a key protein involved in anabolic-catabolic
transition, namely AMPK. The simultaneous blockade of
lactate efflux with ACCA, a specific MCT inhibitor, fur-
ther reduced glioma cell growth. These results were con-
firmed by an in vivo mouse model of glioma, thereby
opening new perspectives for combination therapy in the
treatment of this lethal tumor.
Methods
Materials
Cell culture medium (Dulbecco’s modified minimum
essential medium, DMEM), fetal bovine serum (FBS),
penicillin G, streptomycin, glutamine, sodium pyruvate
and Hoechst were from GIBCO Invitrogen (Carlsbad,
CA); rabbit anti p-AMPKα, AMPKα, were from Cell Sig-
naling (Danvers, MA); anti mouse Gli1 was from Santa
Cruz; 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) salt, DMSO, Hematoxylin & Eosin
were from Sigma-Aldrich (Saint Louis, MO). Glabres-
cione B was synthesized in our laboratory as previously
described [30].
Orthotopic tumor cell injection and intranasal treatment
Eight-week-old male mice were deeply anesthetized and
placed in a stereotaxic head frame. Mice were injected
with 1 × 105 GL261 cells at 2 mm lateral and 1mm
anterior to the bregma in the right striatum. Cell
suspensions, in sterile phosphate buffered saline (PBS)
(4 μl) were injected with a Hamilton syringe at a rate of
1 μl/min at 3 mm depth. After 7 days, mice were intra-
nasally treated with GlaB/mPEG5kDa-Cholane (1.44 mg/
Kg, 40 μl), ACCA (33mM, 6 μl) or mPEG5kDa-Cholane
(40 μl) using the snorting delivery method. Briefly, mice
anaesthetized and maintained with 1.5% isofluorane
(Esteve, UK) were laid on their back. Suspensions were
administered to mice, 3 μl drop at a time, alternating the
nostrils, with a lapse of 1 min between each administra-
tion. GlaB/mPEG5kDa-Cholane treatment was repeated
six times at 2-day intervals. ACCA treatment was daily.
Tumor volume evaluation
Brains were isolated and fixed in 4% buffered p-formal-
dehyde 22 days after GL261 injection. Coronal brain
sections (20 μm) were prepared by standard procedures
and collected every 100 μm. Slices were stained with
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hematoxylin and eosin as detailed by the manufacturer
and tumor area were calculated by the Image Tool 3.0
software (University of Texas, Health Science Center,
San Antonio, TX, USA). Tumor volume was calculated
according to the formula (volume = t × ΣA), where A =
tumor area/slice and t = thickness.
Cell culture
GL261 cells were kindly provided by Dr. Serena
Pellegatta, Neurological Institute “Carlo Besta”, Italy.
GL261 were cultured in DMEM supplemented with 20%
heat-inactivated FBS, 100 IU/ml penicillin G, 100 μg/ml
streptomycin, 2.5 μg/ml amphotericin B, 2 mM glutamine
under the form of L-alanyl-L-glutamine, and 1mM
sodium pyruvate, at 37 °C in a 5% CO2 humidified
atmosphere.
MTT assay
GL261 cells were plated in 96 well plates (5000/well) in
100 μl DMEM + 1% FBS and incubated in the absence or
presence of GlaB (5 μM). After 24 h, 48 h, 72 h and 96 h,
10 μl MTT (5mg/ml) were added to culture medium
and the plate incubated at 37 °C for 90 min. After incu-
bation, the medium was removed and the cells were
solubilized with 100 μl DMSO. Formazan produced by
viable cells was read on microplate reader (Bio-Tek
Instruments, USA) at absorbance of 562–530 nm.
Immunofluorescence
GL261 cells (1 × 105/ well) or pure primary astrocytes
were plated in 24 well plates on glass coverslip. After 48
h, cells were fixed with paraformaldehyde, permeabilized
with 0.2% Triton-X-100, blocked with 1% BSA-PBS and
incubated O/N at 4 °C with a mouse monoclonal
antibody against mouse Gli1 in 0.1% BSA-PBS (1:200,
sc-515,751, Santa Cruz Biotechnology, CA, USA). The
specific protein was visualized using a secondary anti-
body coupled to a fluorescent marker (1:2000 Alexa anti
mouse#594 in 0.1%BS-PBS, 1 h at RT). Nuclei were
stained with Hoechst 33258 (Molecular Probes, Life
Technologies, USA) and examined by fluorescence mi-
croscopy. The images were digitized using a CoolSNAP
camera (Photometrics) coupled to an ECLIPSE Ti-S
microscope (Nikon) and processed using MetaMorph
7.6.5.0 image analysis software (Molecular Device).
Immunofluorescence intensity was quantified by the
integrated intensity density method on automatic thresh-
old analysis.
RNA preparation and qRT-PCR analysis
Total RNA was isolated from cell cultures using Trizol
reagent (Ambion, Life Technologies, USA) according to
the manufacturer’s instructions. The cDNA was prepared
using the iScript Reverse Transcription Supermix (Bio-
Rad Laboratories, USA); the quantitative PCR was per-
formed using the SsoFast Evagreen Supermix (Bio-Rad
Laboratories, USA) according to the protocol for use in
the Biorad I cycler System. For the quantification analysis,
the comparative threshold cycle (Ct) method was used.
The Ct values of each gene were normalized to the Ct
value of Gapdh in the same RNA sample. The gene ex-
pression levels were evaluated by fold change using the
eq. 2-ddCt. Primers used: Gli1 forward: TGAAAACCTC
AAGACGCACC; Gli1 reverse: ACGTATGGCTTCTC
ATTGGAG; Gapdh forward: TCGTCCCGTAGACA
AAATGG; Gapdh reverse: TTGAGGTCAATGAAGG
GGTC.
Western blot
For protein analysis, GL261 cells (2 × 105) were seeded
on 12 well plates and treated with GlaB 5 μM for differ-
ent times (5–10–20-30 min), washed with PBS and lysed
in hot 2x Laemmli buffer, boiled 5 min and sonicated.
The same amount of proteins was separated on 10%
SDS-polyacrylamide gel electrophoresis and analyzed by
western immunoblot using the following primary anti-
bodies: P-AMPKα (1:2500, Cell Signaling), AMPKα
(1:2000, Cell Signaling); HRP-tagged goat anti-mouse
and anti-rabbit IgG were used as a secondary antibody
(1:2000; Dako). Detection was performed through the
chemiluminescent assay Immun-Star Western C Kit
(Bio-Rad, CA) and densitometric analysis was carried
out with Quantity One software (Bio-Rad, CA).
FACS
The FITC-Annexin V Apoptosis Detection Kit (BD
Bioscience, Germany) was used according to the manu-
facturer’s protocol. In brief, treated GL261 cells were
detached and washed twice with cold PBS and resus-
pended in binding buffer at a final density of 106 cells/
ml. FITC-Annexin (5 μl) and PI (5 μl) were added to
100 μl of the cell suspension containing 105 cells. The
cell suspension was mixed by gentle vortexing and then
incubated for 15 min at room temperature in the dark.
Then binding buffer were added and cells were analyzed
by flow cytometry using FACS Calibur (BD Bioscience,
Germany) and the FloWJo software (BD Bioscience).
GL261 cell culture for NMR-metabolomic analysis
For the metabolomic analysis, five independent experi-
ments were performed. In each experiment, confluent
GL261 cells were trypsinized, counted and plated (3 ×
106) in 6 cm dishes containing 1% FBS medium. After
4 h the growth medium was changed and supple-
mented with GlaB 5 μM or vehicle (DMSO) for 12 h
or 24 h or 48 h. In all cases, the culture medium of
each dish was collected, centrifuged (10,000 g for 10
min) and immediately stored at − 80 °C for the exo-
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metabolome analysis. On the other side, cells were ex-
tensively washed (4 times) with ice-cold phosphate-
buffered saline (PBS 1X), in order to completely
remove any residue of culture medium, trypsinized
and centrifuged. Afterwards, cells were dispersed in a
buffer solution containing 10mM Tris (pH 7.4), 5 mM
EDTA, 120mM NaCl, and protease inhibitors (Complete
Protease inhibitor Cocktail tablet, Roche). Cell lysis was
obtained by sonication and the cytosolic fraction contain-
ing the metabolites was obtained upon centrifugation at
17,000 g for 1 h at 4 °C. Subsequently, cytosols were
collected for analysis and stored at − 80 °C for the endo-
metabolome analysis.
NMR sample preparation
Frozen samples were thawed at room temperature and
shaken before use. NMR cell lysate samples were pre-
pared into 5.00 mm NMR tubes (Bruker BioSpin srl)
after the addition of 50 μl of 2H2O containing 10 mM so-
dium 3-trimethylsilyl[2,2,3,3-2H4] propionate (TMSP) to
450 μl of cell lysate. In the case of cell culture media, an
aliquot of 300 μl of a sodium phosphate buffer (70 mM
Na2HPO4; 20% v/v
2H2O; 4.6 mM TMSP, pH was
adjusted to the final value of 7.4 using 1 M HCl) were
added to 300 μl of each medium sample and the mixture
was homogenized by vortexing for 30 s (s). The mixture
was transferred into a 5.00 mm NMR tubes (Bruker
BioSpin srl) for analysis.
NMR experiments
In order to study the possible metabolomic changes in-
duced by GlaB treatment, 1H-NMR spectra were acquired
on both cell lysates and conditioned media verifying their
feasibility and reproducibility (Additional file 1: Figure S1).
NMR spectra were recorded with a Bruker 900-MHz
spectrometer equipped with CP TCI 1H/13C/15N probe.
The 1H-NMR spectra of cell lysates were acquired with
the Carr-Purcell-Meiboom-Gill (CPMG) sequence using a
monodimensional spin–echo sequence with water presa-
turation (cpmgpr, Bruker). 256 scans over a spectral re-
gion of 18 kHz were collected into 110 K points, giving an
acquisition time of 3.07 s. The spectra were recorded with
the CPMG pulse sequence [31] to impose a T2 filter that
allows selective observation of small molecular weight
components. The total T2 delay was set to 290ms. The T2
filtering in the CPMG pulse sequence, which contains
trains of -(τ-180°-τ)- blocks repeated n = 256 times, was
achieved with a total spin-echo delay (2nτ) of 80ms. The
acquisition of each spectrum required about 32min. The
1H-NMR spectra of conditioned media were acquired with
a 1D nuclear Overhauser enhancement spectroscopy
(NOESY)-presaturation pulse sequence (noesygppr1d,
Bruker). A total of 64 scans with 110 K data points were
collected using a spectral width of 17,942Hz, an
acquisition time of 3.07 s, a relaxation delay of 4 s, and a
mixing time of 100ms.
The raw data were multiplied by a 0.3 Hz exponential
line broadening before applying Fourier transform.
Transformed spectra were automatically corrected for
phase and baseline distortions and calibrated (chemical
shift was referenced to the proton of TMSP at δ 0.0
ppm.) using TopSpin 3.5 (Bruker Biospin srl).
Spectral analysis
Each spectrum in the region 10.00–0.2 ppm was seg-
mented into 0.02 ppm chemical shift bins, and the corre-
sponding spectral areas were integrated using the AMIX
software (Bruker). The area of each bin was normalized to
the total spectral area [32], calculated with the exclusion,
for the cell lysates, of the regions 2.55–2.57, 2.69–2.72,
3.20–3.24, 3.6–3.65, 3.67–3.72, 3.75–3.78, 3.79–3.82,
3.86–3.9, 7.65–7.70, 8.05–8.13 ppm (which correspond to
EDTA peaks, Tris peak, and the most intense peaks of the
protease inhibitors used for sample preparation) and 4.5–
5.5 ppm (water region). For the conditioned media exclu-
sion regarded only the water region (4.5–5.0 ppm).
Metabolite statistical analysis
The multivariate and univariate statistical analyses were
performed using R 3.0.2 in house scripts. Multivariate stat-
istical analysis was performed on the obtained buckets; un-
supervised principal component analysis (PCA) was used to
obtain an overview of the data (visualization in a reduced
space, clusters detection, screening for out-layers). The
global accuracy for classification was assessed by means of
a leave-one-out cross-validation scheme (LOOCV).
Twenty-nine and twenty-seven metabolites for cell
lysates and conditioned media, respectively, were
assigned (Additional file 2: Table S1) and their levels an-
alyzed. The assignment procedure was made up using a
NMR spectra library of pure organic compounds, public
databases (e.g. Human Metabolome Database-HMBD,
Additional file 2: Table S1), stored reference NMR spec-
tra of metabolites, spiking NMR experiments and using
data available in literature. Matching between new NMR
data and databases was performed using the AMIX
software. The relative concentrations of the various
metabolites were calculated by integrating the corre-
sponding signals in the spectra with an in-house script.
The non-parametric Wilcoxon test was used for the
determination of the meaningful metabolites: a p-value
of 0.05 was considered statistically significant.
GlaB brain level concentration measured by HPLC
coupled with electrospray mass spectrometry
Sample preparation
HPLC-MS analyses were performed on three independ-
ent experiments of brain samples from mice treated with
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GlaB/mPEG5kDa-Cholane. The brain sample (500 mg),
previously stored at − 80 °C for 24 h, was homogenized
with 1 ml of a Phosphate Buffered Saline solution, PBS,
using an ultrasound probe. A solution of ZnSO4 (0.1 M
in H2O, 1 ml) and acetonitrile for HPLC (1 ml) was
added to the mixture, which was further homogenized
with ultrasound for 15 min. Subsequently, the homogen-
ate brain was stirred for 1 h at room temperature and
was then centrifuged at 3000 g for 5 min at T = 4 °C. The
supernatant was collected. The following procedure to
obtain the brain extract was repeated twice. Acetonitrile
for HPLC (1 ml) was added to the brain residue, stirred
for 30 min at room temperature, then centrifuged at
3000 g for 5 min at T = 4 °C and the supernatant col-
lected. Brain extract samples were centrifuged for 5 min
at 5000 g and 20 μl of supernatant injected into the
HPLC-MS without further treatments.
Equipment and chromatographic conditions
The HPLC chromatographic system used was an UltiMate
3000 RS system (Thermo Fisher Dionex Sunnyvale,
California), equipped with an UltiMate 3000 LPG-3400RS
Low Pressure Mixing Biocompatible Gradient Pump, an
UltiMate 3000 WPS-3000TSL Analytical Autosampler
with a thermostated analytical scale in-line split loop in-
jection principle, a thermostated column ventilated com-
partment (temperature range: 5–110 °C) and a diode array
detector (UltiMate 3000 DAD-3000RS Rapid Separation
Diode Array Detector, up to 200 Hz acquisition rate) with
a low dispersion 13 μl flow cell. The stationary phase used
was a Titan C18 (100 × 3.0 mm LxI.D. 1.9 μm). All chro-
matographic runs were performed at a flow-rate of 0.4 ml/
min with the column equilibrated at 35 °C. Solvent A was
Water/Acetonitrile 90:10 with 0.1% v/v of formic acid, and
solvent B was Acetonitrile/Methanol 50:50 with 0.1% v/v
of formic acid. The gradient was set as shown in
Additional file 2: Table S2. The LC was directly interfaced
to electrospray ionization (ESI) source coupled with a
Single Quadrupole-MSQ Plus Detector. Ion source was
operated in positive ESI mode and both Full Scan and
SIM (m/z = 451, corresponding to the most abundant ion
[M+H]+ of GlaB, from 22 to 27min) were acquired for
each sample. Optimal instrument source parameters for
ionization were a cone voltage of 100 V and a Probe
Temperature of 550 °C.
Sample quantification
Calibration curves were built both in UV (254 nm) and
MS in SIM mode, by monitoring the m/z = 451 corre-
sponding to the most abundant ion [M +H]+ of GlaB.
Calibration standards ranged from 0.743 to 7.938 μg/
ml for UV curve (y = 0.2379x-0.0779, R2 = 1) with a
Limit of Quantitation, LOQ, (defined for a signal-to-
noise ratio > 10) of 1.48 ng on column, while for MS plot
the lower range is 0.309 μg/ml showing a good linearity
(y = 11,655x-2890.2, R2 = 1) with a LOQ of 0.62 ng on
column (Additional file 1: Figure S2).
A known amount (0.45 μg/ml) of the GlaB analyte
(a spike) was added to treated brain sample. The sam-
ples and the samples plus spike were then analyzed
(Additional file 1: Figure S3). The sample with the
spike will show a larger analytical response than the
original sample due to the additional amount of ana-
lyte added to it. The difference in analytical response
between the spiked and unspiked samples is due to
the amount of analyte in the spike. This provides a
calibration point to determine the analyte concentra-
tion in the original sample.
Results
GL261 cells overexpress Gli1 and its inhibition with GlaB
induces cell apoptosis
In order to investigate Hh signaling in glioma, we mea-
sured the expression of Gli1 by RT-PCR and by
immunofluorescence. The mRNA expression of Gli1 is
shown in Fig. 1a, with GL261 cells expressing about 6-
fold higher level of Gli1 than primary astrocytes. GlaB
treatment (5 μM, 48 h) significantly decreased Gli1 tran-
scription, indicating that the Hh signaling has a basal
activity and that Gli1 is functionally expressed in these
cells. Qualitatively similar results were obtained by
immunofluorescence analyses (Fig. 1b and c). Staining
with secondary antibody alone was performed as a con-
trol for specificity. In order to investigate the role of
Gli1 in GL261 proliferation, we evaluated the effect of
GlaB treatment (5 μM) on cell viability. As shown in
Fig. 1d, GlaB treatment (48 h–72 h) significantly reduced
cell viability. It has been shown that Gli1 inhibition
could promote apoptosis in other cancer cells [33, 34].
We investigated whether GlaB treatment could induce
programmed cell death in GL261 cells, by cytofluori-
metric analysis of Annexin V staining and Propidium
Iodide (PI) incorporation. Figure 1e shows that GlaB in-
creased apoptosis at 48 h (measured as the sum of early
-Annexin V positive- and late apoptotic -Annexin V +
Annexin V/PI- positive cells) compared to control cells,
indicating that GlaB treatment reduces cell proliferation
and promotes apoptosis in glioma cells.
GlaB treatment affects the metabolomic profiles of GL261
cells, exacerbating the Warburg effect
To investigate possible metabolic effects of GlaB in
GL261 cells, we performed an untargeted 1H-NMR
metabolic profiling on cellular lysates and growth media.
1H-NMR spectra were acquired in order to determine
the metabolic fingerprints of GL261 untreated and
GlaB-treated cells, at different time points (12 h, 24 h,
and 48 h). Multivariate unsupervised PCA analysis
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performed on the acquired 1H-NMR spectra, clearly
shows the strong remodeling of the metabolomic pheno-
typing of GL261 cells, upon GlaB treatment. Both the
endo- and the exo-metabolome of GL261 cells were
significantly modified by GlaB administration, with a
discrimination accuracy among the six different groups
ranging from 86.7% (lysates) to 100% (growing media)
(Fig. 2a). The alteration of GL261 metabolomic profile
was evident already after 12 h of treatment, both in the
cell lysates and in the growth media. The 95% confi-
dence level ellipses (Fig. 2a) for cell lysates at 12 h and
24 h are almost overlapping in untreated cells, while they
are better separated, even if still close, in treated cells.
The separation increases at 48 h, again with larger differ-
ences for the treated cell lysates, indicating that the
metabolomic profile of cells was heavily altered by GlaB.
An analogous trend is observed for media, although they
are characterized by more homogeneous composition
within each group (Fig. 2a). The observed trends suggest
the presence of a sort of biphasic behavior, which reflects
the effects on cell viability in Fig. 1c. When cell viability
remains constant in untreated cells, the metabolome
undergoes only minor shifts. The metabolic drift is more
accentuated in GlaB-treated cells, where the initial ef-
fect of the drug becomes visible. At 48 h both cell types
are in a growing phase, but GlaB-treated cells showed
higher frequency of apoptotic cells compared to control
(Fig. 1e). The Additional file 2: Table S1 reports all the
assigned metabolites both in the cell lysates and in the
extracellular media. The changes in metabolite concentra-
tions for each time point are shown in Fig. 2 and in the
Additional file 1: Figure S4 and S5, as they result from
univariate analyses, and reflect the multiphase behavior
described above. In GlaB-treated cells we found that the
levels of several endo-metabolites are lower than in the
untreated controls, both at 12 h and 24 h. These metabo-
lites include glucose-6-phosphate, some amino acids (e.g,
isoleucine, leucine, valine, phenylalanine, histidine, tyro-
sine, threonine, glutamate, aspartate, arginine, glutamine,
N-acetylaspartate) and other molecules (e.g. choline, ca-
daverine, AXP-shorthand to indicate the not unambigu-
ously assigned signals of ATP, ADP and AMP, formate,
Fig. 1 Murine glioma GL261 cells are Hedgehog dependent tumor cells. a Data (mean ± se) are normalized to Gapdh mRNA expression and are
expressed as Gli1 mRNA fold increase vs Gli1 mRNA expression levels on astrocytes. One-way ANOVA, **p < 0.01, n = 7. b Immunofluorescence
images of Gli1 protein (RED) in Astrocytes, GL261 and GL261 + GlaB treated (5 μM, 48 h) cells. c Protein signal quantification in Astrocytes, GL261
and GL261 + GlaB treated (5 μM, 48 h) cells. Nuclei were visualized by Hoechst (BLU) scale bar: 20 μm. One-way ANOVA, **p < 0.01, n = 10. d MTT
growth curves in untreated and GlaB treated cells (5 μM, 24 h, 48 h, 72 h) data are expressed as mean ± se, *p < 0.05, n = 3 (each in quadruplicate).
e Apoptosis measured as the sum of cells positive for Annexin V and Annexin V/PI double positive cells in GL261 untreated or treated with GlaB
5 μM for 48 h, data are expressed as mean ± se, ***p < 0.001, n = 3 (each in duplicate)
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myo-inositol, creatine and creatinephosphate) (Fig. 2c,
and Additional file 1: Figure S4). On the contrary, the
levels of the endogenous products of the aerobic glycolysis
(e.g. pyruvate, lactate and alanine) increased significantly
(Fig. 2c, and Additional file 1: Figure S4). The behavior of
the metabolites of the TCA cycle is more complex with
Fig. 2 GlaB treatment significantly altered (*) the metabolic profile of GL261 cells. a Metabolomic phenotyping of cell lysates (left panel,
endo-metabolome) and respective growth media (right panel, exo-metabolome) after 12 h, 24 h and 48 h of GlaB treatment. Score plots of PCA:
PC1 vs PC2. The 6-group discrimination accuracy values are also reported. In the score plots, each dot represents a different sample, and each
color represents a different group of samples: blue dots, 12-CTR; red dots, 24-CTR; purple dots, 48-CTR; green dots, 12-GLAB; orange dots, 24-
GLAB; cyan dots, 48-GLAB. b Schematic representation of glycolysis and TCA cycle in GL261 cells. c Box plots showing the altered intracellular
glycolytic metabolites over time. d Box plots showing the altered extracellular glycolytic metabolites over time. e Box plots showing the altered
intracellular TCA-metabolites over time. f Box plots showing the altered intracellular TCA-related metabolites over time. g Box plots showing the
altered extracellular TCA-metabolites over time. Data are expressed as mean ± se, n = 5 *p < 0.05 vs respective control. h Western blot analysis of
GlaB treated (5 μM) GL261 cells at indicated time point for AMPK phosphorylation. Quantification of protein expression by densitometry analysis of
the bands. Data are expressed as fold increase over control of phospho/total protein ratio of Ampk. Statistical analysis: One-way ANOVA followed
by Dunn’s post hoc test *p≤ 0.05. On the right, representative western blots
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decreased levels of citrate and malate, and increased levels
of succinate and fumarate (Fig. 2e and Additional file 1:
Figure S4).
The univariate statistical analysis of fresh and spent
culture media also revealed essential differences in the
uptake and release of metabolites: GlaB treatment for
12 h and 24 h significantly enhanced the release into the
media of lactate and alanine. In contrast, the treatment
enhanced the consumption of extracellular glucose over
time. Pyruvate uptake was lower after 12 h and 24 h of
treatment (Fig. 2d and Additional file 1: Figure S5). The
uptake of the amino acids isoleucine and leucine
decreased starting from 12 h of GlaB administration.
Finally, the net changes in glycine levels go into opposite
directions in treated and untreated cells; in the former,
glycine is taken up as a consequence of GlaB treatment,
while in the latter it is released into the media
(Additional file 1: Figure S5). At later time point (48 h),
stronger variations are observed: pyruvate uptake is lar-
ger in treated vs untreated cells, while its intracellular
levels are similar. The extracellular levels of lactate in
GlaB-treated cells increase significantly (Fig. 2c and d),
as well as the intracellular alanine (Additional file 1:
Figure S4). The extracellular levels of tyrosine, phenyl-
alanine and histidine remain constant at 24 h and 48 h,
while their intracellular levels are decreased in treated and
untreated cells, suggesting their augmented consumption
to sustain glioma growth. Intracellular leucine, isoleucine,
valine also decrease in GlaB-treated cells, while a corre-
sponding reduction of extracellular consumption is ob-
served (Additional file 1: Figure S4 and S5).
Intracellular AXP levels drop upon GlaB treatment at
12 h and 24 h (Additional file 1: Figure S4). At 48 h, a
significant increase of glutamine excretion is observed
(Additional file 1: Figure S5).
As concern the TCA cycle metabolites, particularly
relevant is the increase of succinate at the intra- and
extracellular levels in GlaB treated samples, and the in-
crease of citrate at extracellular level in both conditions
(Fig. 2e and g).
Additionally, in cell lysates, significant decrements
of the broad signals derived from macromolecule
spectral components (e.g., lipids, lipoproteins and
proteins) can be detected at 48 h of treatment
(Additional file 1: Figure S6).
The anabolic-catabolic transition, together with the
reduction of AXP levels, (Additional file 1: Figure S5)
induced by GlaB treatment of GL261 cells, suggests that
this molecule can favor energy stress in glioma. This
hypothesis is further supported by the increased phos-
phorylation levels of the energy sensor AMPK. Indeed,
data shown in Fig. 2h demonstrate that GlaB treatment
(5 μM) significantly changed the phosphorylation level of
this protein.
GlaB/ACCA co-treatment induces GL261 cell necrosis
Since GlaB-treated GL261 cells show an increased War-
burg-like metabolism, we investigated if the corresponding
increase of lactate was involved in GlaB-induced modula-
tion of cell viability. At this aim, cells were treated with
ACCA (250 μM), a small-molecule competitive inhibitor of
lactate transporters, and analyzed for cell growth, apop-
tosis and necrosis in the presence or absence of GlaB
(5 μM). Previous studies demonstrated that ACCA induced
tumor cell death, both in vivo and in vitro [25, 26].
As shown in Fig. 3a, ACCA treatment impairs GL261
viability, similarly to GlaB, and this effect was potentiated
in GlaB/ACCA treated cells. ACCA treatment increased
GL261 apoptosis (48 h), seen as Annexin V positive +
Annexin V/PI positive cells (Fig. 3b and Additional file 1:
Figure S7), as already reported for other glioma cells [25].
Co-treatment with GlaB/ACCA occluded the induction of
apoptosis (Fig. 3b and Additional file 1: Figure S7) but
switched the effect on cell viability to cell necrosis (PI
positive cells) (Fig. 3c and Additional file 1: Figure S7).
These data support the hypothesis that the increased
glycolytic flux induced by GlaB promotes apoptosis in
glioma cells, and that the blockade of lactate efflux trans-
forms an otherwise programmed cell death in a less regu-
lated, necrotic process.
Effect of GlaB and GlaB/ACCA treatment in mouse model
of glioma
To verify the translational potential of GlaB effects on
tumor growth, we used a mouse model of glioma.
C57BL6 mice were intracerebrally injected with syngen-
eic GL261 cells in the right striatum and, after 7 days,
animals were intranasally treated with GlaB (1.44 mg/Kg,
drug formulated with mPEG5kDa-Cholane, see methods),
every two days, for six times, alone or in combination
with ACCA (33 mM, 6 μl) administered every day.
To verify brain delivery, we measured GlaB concentra-
tion in brain extracts of GlaB treated mice, by HPLC
coupled with Electrospray Mass Spectrometry. The ana-
lytical method used the reversed phase chromathography
and showed a high sensitivity (Additional file 1: Figure
S2), leading to the quantification of GlaB present in
brain extracts. Two hours after the first IN administra-
tion (GlaB/mPEG5kDa-Cholane formulation), we evalu-
ated the presence of the drug (Fig. 4a, grey line) and
quantified a mean value of 4.77 ± 0.35 μg/g of GlaB brain
extract (Additional file 1: Figure S2 and S3). As shown
in Fig. 4b, GlaB administration significantly reduced
tumor volume, in comparison with vehicle-treated mice.
GlaB/ACCA co-administration further reduced tumor
volume compared with GlaB treatment alone, demon-
strating that, in vivo, the blockade of lactate efflux
potentiates the GlaB effect.
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Fig. 3 Blockade of lactate transport increases GlaB effect. a MTT assay showing that ACCA treatment (250 μM) and GlaB treatment (5 μM) at
indicated time points reduced growth of GL261 cells and that this effect was higher when cells were treated with both. Data are expressed as
mean ± se, n = 3 (each in quadruplicate), *p < 0.05 vs control, #p < 0.05 vs GlaB+ACCA by One-way ANOVA followed by Student-Neuman-Keuls
(SNK) post-test. b Cytofluorimetry study showing that the treatment of GL261 with ACCA (100 μM, 48 h) increases the percentage of apoptotic
cells (n = 4, One-way ANOVA, SNK test, data are expressed as mean ± se, ***p < 0.001 vs control). c Cytofluorimetry study showing that the co-
treatment of GL261 with GlaB and ACCA (5 μM and 100 μM respectively) for 48 h increases the percentage of cells featuring non-apoptotic/
necrosis like death, measured with Propidium Iodide (PI) staining (n = 4, One-way ANOVA, SNK test, ***p < 0.001 vs control)
Fig. 4 GlaB and GlaB/ACCA treatment in vivo is effective in glioma-bearing mice. a Extraction chromatograms (XIC) referred to brain extract
of GlaB IN treated mice (a) and vehicle mice (b). GlaB peak at known retention time (Rt) of 25.00 min is shown and detected in IN treated sample
and is missing in control. * The peak at Rt: 23.90 min is the isotopic abundance with m/z = 451 of an unknown peak with m/z = 449, present in all
brain extracts. b Tumor volume (mm3) in GL261-bearing mice intra-nasally treated with GlaB (PEG-Cholane GlaB 1.44 mg/Kg), GlaB+ACCA (6 μl 33
mM) or vehicle (PEG-Cholane). Data are expressed as mean ± se, *p < 0.05 vs control, #p < 0.05 vs GlaB, One-way ANOVA n = 8
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Discussion
Since every cellular process has a defined metabolic fin-
gerprint, the cell metabolomic approach is becoming
one of the most-used tools to investigate crucial path-
ways in cancer development and drug-induced effects
[24, 35–38]. The metabolism of cancer cells differs from
that of normal cells: high-grade tumors, including GBM,
must balance energy metabolism to synthesize the mac-
romolecules essential for growth and progression relying
on anaerobic metabolism, even under physiological oxy-
gen levels [21, 39]. The tumor microenvironment also
affects cancer cell proliferation, thus influencing treat-
ment responses [40–42]. It has been reported that GBM
cells in culture convert as much as 90% of glucose and
60% of glutamine they acquire into lactate or alanine
[43]. Using an untargeted NMR approach, we measured
the endo- and exo-metabolome of GlaB-treated and
untreated cells and identified altered levels of metabo-
lites over time.
While the changes of metabolite concentration levels
at 12 h and 24 h can be explained as a direct and early
consequence of GlaB effects on the metabolism, the
changes at 48 h are of more difficult interpretation, being
the combination of multiple effects. In particular, the
intracellular increasing levels of lactate accompanied by
the decreasing levels of glucose-6-phosphate demonstrate
that GlaB exacerbates the Warburg effect. Consistently,
GlaB-treated cells showed increased glucose uptake from
the growing media and increased lactate excretion, likely
to avoid cellular acidification. This metabolomic pattern,
with the additional observation of both intracellular and
extracellular increase in alanine concentration, reflect an
enhanced glycolytic metabolism and high lactate produc-
tion (Fig. 2). Pyruvate levels are also significantly increased
by GlaB treatment at 12 h and 24 h. The higher intracellu-
lar levels of pyruvate can be explained as a sum of
enhanced glycolysis and hindered TCA cycle. In fact, the
alteration pattern of citrate, succinate, fumarate and mal-
ate levels suggests the presence of a truncated TCA cycle
[43] in GlaB-treated cells. The absence of a fully functional
TCA cycle in GlaB-treated cells is in accordance with the
intracellular reduction of amino acids like glutamate,
branched-chain amino acids and aspartate. The intracellu-
lar levels of glutamate progressively increased over time,
but significantly reduced in GlaB-treated cells. This trend
might suggest an inhibition of the mitochondrial enzyme
glutaminase [44]. Moreover, the lower levels of isoleucine,
leucine and valine in treated cells reinforce the hypothesis
of reduced anaplerotic reactions as a consequence of a
truncated TCA cycle [45–48]. The intracellular levels of
aspartate and its derivative N-acetylaspartate are signifi-
cantly decreased in GlaB-treated cells. Aspartate consti-
tutes a key metabolic hub in the cells, being a major
precursor for protein and nucleotide biosynthesis, as well
as critical for the synthesis of other “non-essential” amino
acids such as asparagine (below the NMR detection limit)
and arginine (which also decreases upon GlaB treatment).
Metabolic data suggest that GlaB increased the glyco-
lytic metabolism of GL261 cells, and the phosphorylation
of proteins involved in the anabolic to catabolic transition,
such as AMPK. These effects could be a consequence of
the GlaB-induced reduction of intracellular levels of ATP
[49], thus leading to the hypothesis that GlaB could favor
energy stress in glioma. We also found that the increased
lactate extrusion induced by GlaB treatment is important
to prevent lactate “self-poisoning”, as already described for
astrocytes and glioma cells [26]. Indeed, the blockade of
lactate efflux by ACCA induced GL261 cell death by
apoptosis, as already reported [25, 26]. The effect on cell
viability was enhanced when lactate efflux was blocked
simultaneously to GlaB treatment, with the induction of
necrotic cell death. To test the translational potential of
GlaB and GlaB/ACCA treatments, we used the syngeneic
GL261 glioma model and delivered GlaB intranasally.
Intranasal administration is commonly used to treat neu-
rodegenerative diseases, to bypass the obstacle provided
by the BBB [50]. With this treatment, GlaB accumulates
in the brain, and efficiently reduces tumor volumes both
in GlaB and in GlaB/ACCA treated mice.
Conclusions
In this manuscript, we show for the first time the effect of
an established Hh pathway inhibitor, GlaB, on glioma cell
growth and metabolism, using in vitro and in vivo models
of the pathology. In particular, we established by using
NMR-based metabolomics analysis that GlaB treatment in-
duces metabolic alterations in GL261 cells improving the
glycolytic process over the TCA. Accordingly, we found
that GlaB/ACCA treatment amplifies the anti-tumor
effects of the single molecules, increasing cell necrosis and
reducing tumor size in in vivo model of glioma. Our results
could pave the road for future therapeutic strategies against
human glioma and provide evidence that metabolomic
analysis of cultured tumor cells is a valid method to study
the metabolic alterations accountable for drug treatment.
Although we found that the metabolites related to glycoly-
sis are significantly associated with GlaB treatment of gli-
oma cells, future works should be performed to further
understand the molecular mechanism involved.
Additional files
Additional file 1: Figure S1. The endo- and exo-metabolome
assignment of GL261 cell line. Full region of the 1H-NMR spectra of cell
lysates (A) and growing media (B) along with the assignment of the
most intense metabolites, with the exclusion of water region. Figure S2.
Chromatograms for estimated LOQ in UV and MS. (A) LOQ in UV
determination is 1.48 ng of GlaB on column with a S/N = 16.7 for UV
chromatogram and a S/N = 68.6 for MS trace. (B) LOQ in MS
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determination is 0.62 ng of GlaB on column with a S/N = 1.67 for UV
chromatogram and a S/N = 13.6 for MS trace. Figure S3. Extract ion
chromatograms (XIC) referred to IN treated sample (A) and spiked IN
(0.45 μg/ml, 9 ng on column) treated sample (B). Both traces show the
presence of GlaB peak (Rt: 25.00). * The peak at Rt: 23.90 min is the
isotopic abundance with m/z = 451 of an unknown peak with m/z = 449,
present in all brain extracts. Figure S4. Univariate analysis of the relative
concentration levels of characteristic GL261 endo-metabolites. The box
plots show the comparison of the relative intensities of the indicated
metabolites between the untreated (CTR, light blue boxes) and treated
(GlaB, orange boxes) groups at each time point. Metabolites whose
concentration is significantly different (p-value < 0.05, by non-parametric
Wilcoxon test) are marked with *. Figure S5. Univariate analysis of the
relative concentration levels of GL261 exo-metabolites. The box plots show
the comparison of the relative intensities of the indicated metabolites
between the untreated (CTR, light blue boxes) and treated (GlaB, orange
boxes) groups at each time point. Metabolites whose concentration is
significantly different (p-value < 0.05, by non-parametric Wilcoxon test) are
marked with *. The relative concentration levels of DMEM medium are also
reported as Blank. Figure S6. Upfield region (0.75–1.8 ppm) of 1H-NMR
CPMG spectra of cell lysates (endo-metabolome). Blue tracks, 12-CTR; red
tracks, 24-CTR; purple tracks, 48-CTR; green tracks, 12-GLAB; orange tracks,
24-GLAB; cyan tracks, 48-GLAB. Figure S7. Representative FACS analyses
showing the percentage of Annexin V/Propidium Iodide of cell population
in GL261 untreated, treated with GlaB (5 μM), ACCA (250 μM) or both for 48
h. (DOCX 4706 kb)
Additional file 2: Table S1. List of the endo- and exo-metabolites
assigned and analysed over time before and after GlaB treatment.
Metabolites realised from GL261 cells after 48 h of treatment are reported
separately. The Human Metabolome Database (HMDB) compound ID of
each metabolite is also reported. Table S2. The HPLC gradient for the
brain extracts analysis. All chromatographic runs were performed at a
flow-rate of 0.4 ml/min. Solvent A was Water/Acetonitrile 90:10 with the
0.1% v/v of formic acid, and solvent B was Acetonitrile/Methanol 50:50
with the 0.1% v/v of formic acid. (DOCX 117 kb)
Abbreviations
ACCA: α-cyano-4-hydroxycinnamic acid; AMPK: AMP activated protein Kinase;
BBB: Blood brain barrier; CNS: Central nervous system; CPMG: Carr-Purcell-
Meiboom-Gill; Ct: Threshold cycle; Dhh: Desert hedgehog; DMEM: Dulbecco’s
modified minimum essential medium; DMSO: Dimethyl sulfoxide;
ESI: Electrospray ionization; FACS: Fluorescence-activated cell sorting;
FBS: Fetal bovine serum; GBM: Glioblastoma; GL261: Murine glioma cells;
GlaB: Glabrescione B; Hh: Hedgehog; HMDB: Human metabolome database;
HPLC: High Performance Liquid Chromatography; Ihh: Indian hedgehog;
IN: Intranasal; LOOCV: Leave-one-out cross-validation; LOQ: Limit of
quantitation; MCTs: mono-carboxylate transporters; MS: Mass Spectrometry;
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
NMR: Nuclear magnetic resonance; NOESY: Nuclear overhauser enhancement
spectroscopy; PBS: Phosphate buffered saline; PCA: Principal component
analysis; PI: Propidium iodide; Ptch: Patched; Shh: Sonic hedgehog;
Smo: Smoothened; TCA: Tricarboxylic acid cycle; TMSP: Sodium 3-
trimethylsilyl [2,2,3,3-2H4] propionate
Acknowledgements
PT, VG and DQ acknowledge the support and the use of resources of
Instruct-ERIC, a Landmark ESFRI project, and specifically the CERM/CIRMMP
Italy Centre.
Authors’ contributions
GDA and DQ designed and conducted most of the experiments in vitro and
in vivo, provided overall guidance and contributed to manuscript writing.
LM, CLauro, AP, MADC and SF conducted molecular biology experiments. FG
and CI performed the synthesis and characterization of the bioactive
compound and interpretation of HPLC data. MDM designed and performed
the HPLC analyses. FB and FM performed the preparation of drug-
formulation. MM contributed to experimental design and manuscript writing.
PI contributed to manuscript writing. PT designed NMR metabolomic
experiments and participated to manuscript writing and reviewing. SS and
PC designed drug-formulation and contributed to manuscript writing. LDM
and BB conceived the project and provided overall guidance. VG performed
the acquisition and interpretation of NMR metabolomic data. CL conceived
the project, provided overall guidance and wrote the manuscript. All authors
read and approved the final manuscript.
Authors’ information
Not applicable.
Funding
This work was supported by AIRC IG2015–16699 to CL and IG2017–20801 to
LDM, by Cost Action CM1407 to BB and by Ricerca Finalizzata (MoH) to CL.
VG was supported by AIRC fellowship for Italy. PT acknowledges Fondazione
Cassa di Risparmio di Firenze for funding the project “Advanced mass
spectrometry tools for cancer research: novel applications in proteomics,
metabolomics and nanomedicine”. This work has been supported by Italian
Ministry of Education, University and Research - Dipartimenti di Eccellenza -
L.232/2016.
Availability of data and materials
The datasets used and/or analyzed during the current study are available on
reasonable request.
Ethics approval and consent to participate
Experiments described in the present work were approved by the Italian
Ministry of Health in accordance with the guidelines on the ethical use of
animals from the European Community Council Directive of 22 September
2010 (2010/63/EU). All efforts were made to minimize the number of animals
used and their suffering. We used male C57BL/6 mice from Charles River
Laboratories.
Consent for publication
All authors agreed on the manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Physiology and Pharmacology, Sapienza University, Rome,
Italy. 2IRCCS Neuromed, Pozzilli, IS, Italy. 3Department of Chemistry and
Technology of Drugs, “Department of Excellence 2018−2022”, Sapienza
University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy. 4Center For Life
Nano Science@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy.
5Department of Molecular Medicine, Laboratory affiliated to Istituto Pasteur
Italia Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy.
6Department of Pharmaceutical and Pharmacological Sciences, University of
Padova, Padova, Italy. 7Department of Biotechnology, Chemistry and
Pharmacy, “Department of Excellence 2018−2022”, University of Siena, via
Aldo Moro 2, 53100 Siena, Italy. 8CERM and Department of Chemistry,
University of Florence, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Florence,
Italy. 9CIRMMP, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Florence, Italy.
10Department of Physiology and Pharmacology, Laboratory affiliated to
Istituto Pasteur Italia Fondazione Cenci Bolognetti, Sapienza University of
Rome, Rome, Italy.
Received: 13 June 2019 Accepted: 14 August 2019
References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al.
The 2007 WHO classification of tumours of the central nervous system. Acta
Neuropathol. 2007;114:97–109.
2. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The
epidemiology of glioma in adults: a “state of the science” review. Neuro-
Oncology. 2014;16:896–913.
3. Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SAA, et al. Current
status and future therapeutic perspectives of glioblastoma multiforme
(GBM) therapy: a review. Biomed Pharmacother. 2017;92:681–9.
4. Riobo NA, Manning DR. Pathways of signal transduction employed by
vertebrate hedgehogs. Biochem J. 2007;403:369–79.
5. Teglund S, Toftgård R. Hedgehog beyond medulloblastoma and basal cell
carcinoma. Biochim Biophys Acta. 1805;2010:181–208.
D’Alessandro et al. Cell Communication and Signaling          (2019) 17:108 Page 11 of 12
6. Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C. Interactions
between hedgehog proteins and their binding partners come into view.
Genes Dev. 2010;24:2001–12.
7. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting
notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update.
Nat Rev Clin Oncol. 2015;12:445–64.
8. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW, et al. A stochastic
model for cancer stem cell origin in metastatic colon cancer. Cancer Res.
2008;68:6932–41.
9. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the
hedgehog pathway in cancer. Nat Med. 2013;19:1410–22.
10. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins
DN, et al. Medulloblastoma growth inhibition by hedgehog pathway
blockade. Science. 2002;297:1559–61.
11. Graab U, Hahn H, Fulda S. Identification of a novel synthetic lethality of
combined inhibition of hedgehog and PI3K signaling in
rhabdomyosarcoma. Oncotarget. 2015;6:8722–35.
12. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, et al.
Melanomas require HEDGEHOG-GLI signaling regulated by interactions
between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A.
2007;104:5895–900.
13. Tojo M, Kiyosawa H, Iwatsuki K, Kaneko F. Expression of a sonic hedgehog
signal transducer, hedgehog-interacting protein, by human basal cell
carcinoma. Br J Dermatol. 2002;146:69–73.
14. Clement V, Sanchez P, De Tribolet N, Radovanovic I, Ruiz I, Altaba A.
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem
cell self-renewal, and tumorigenicity. Curr Biol. 2007;17:165–72.
15. Uchida H, Arita K, Yunoue S, Yonezawa H, Shinsato Y, Kawano H, et al. Role
of sonic hedgehog signaling in migration of cell lines established from
CD133-positive malignant glioma cells. J Neuro-Oncol. 2011;104:697–704.
16. Yan GN, Yang L, Lv YF, Shi Y, Shen LL, Yao XH, et al. Endothelial cells
promote stem-like phenotype of glioma cells through activating the
hedgehog pathway. J Pathol. 2014;234:11–22.
17. Zhou A, Lin K, Zhang S, Ma L, Xue J, Morris SA, et al. Gli1-induced
deubiquitinase USP48 aids glioblastoma tumorigenesis by stabilizing Gli.
EMBO Rep. 2017;18:1318–30.
18. Di Magno L, Basile A, Coni S, Manni S, Sdruscia G, D’Amico D, et al. The
energy sensor AMPK regulates hedgehog signaling in human cells through
a unique Gli1 metabolic checkpoint. Oncotarget. 2016;7:9538–49.
19. Infante P, Mori M, Alfonsi R, Ghirga F, Aiello F, Toscano S, et al. Gli1/DNA
interaction is a druggable target for hedgehog-dependent tumors. EMBO J.
2015;34:200–17.
20. Ghirga F, Mori M, Infante P. Current trends in hedgehog signaling pathway
inhibition by small molecules. Bioorg Med Chem Lett. 2018;28:3131–40.
21. Warburg OH. The metabolism of tumours (translated by Dickens F). London:
Constable; 1930.
22. Pavlova NN, Thompson CB. The emerging hallmarks of Cancer metabolism.
Cell Metab. 2016;23:27–47.
23. Strickland M, Stoll EA. Metabolic reprogramming in glioma. Front Cell Dev
Biol. 2017;5:43.
24. Bernacchioni C, Ghini V, Cencetti F, Japtok L, Donati C, Bruni P, et al. NMR
metabolomics highlights sphingosine kinase-1 as a new molecular switch in
the orchestration of aberrant metabolic phenotype in cancer cells. Mol
Oncol. 2017;11:517–33.
25. Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, et al. Metabolic
targeting of lactate efflux by malignant glioma inhibits invasiveness and
induces necrosis: an in vivo study. Neoplasia. 2011;13:620–32.
26. Caruso JP, Koch BJ, Benson PD, Varughese E, Monterey MD, Lee AE, et al. pH,
lactate, and hypoxia: reciprocity in regulating high-affinity Monocarboxylate
transporter expression in glioblastoma. Neoplasia. 2017;19:121–34.
27. Ippolito L, Morandi A, Giannoni E, Chiarugi P. Lactate: a metabolic driver in
the tumour landscape. Trends Biochem Sci. 2019;44:153–66.
28. Vignoli A, Ghini V, Meoni G, Licari C, Takis PG, Tenori L, et al. High-throughput
metabolomics by 1D NMR. Angew Chem Int Ed Engl. 2019;58:968–94.
29. Takis PG, Ghini V, Tenori L, Turano P, Luchinat C. Uniqueness of the NMR
approach to metabolomics. TrAC Trends Anal Chem. 2018. https://doi.org/1
0.1016/j.trac.2018.10.036.
30. Ingallina C, Costa PM, Ghirga F, Klippstein R, Wang JT, Berardozzi S, et al.
Polymeric glabrescione B nanocapsules for passive targeting of hedgehog-
dependent tumor therapy in vitro. Nanomedicine. 2017;12:711–28.
31. Carr HY, Purcell EM. Effects of diffusion on free precession in nuclear
magnetic resonance experiments. Phys Rev. 1954;94:630.
32. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization
effects in NMR spectroscopic metabonomic data sets. Anal Chem. 2006;78:2262–7.
33. Nakamura S, Nagano S, Nagao H, Ishidou Y, Yokouchi M, Abematsu M, et al.
Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI
transcription via DNA damage accumulation. PLoS One. 2013;8:e69466.
34. Han JB, Sang F, Chang JJ, Hua YQ, Shi WD, Tang LH, et al. Arsenic trioxide
inhibits viability of pancreatic cancer stem cells in culture and in a xenograft
model via binding to SHH-Gli. Onco Targets Ther. 2013;6:1129–38.
35. García-Cañaveras JC, Castell JV, Donato MT, Lahoz A. A metabolomics cell-
based approach for anticipating and investigating drug-induced liver injury.
Sci Rep. 2016;6:27239.
36. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer.
2004;4:551–61.
37. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and
towards mechanisms. Nat Rev Mol Cell Biol. 2016;17:451–9.
38. Ghini V, Di Nunzio M, Tenori L, Valli V, Danesi F, Capozzi F, et al. Evidence of
a DHA signature in the Lipidome and metabolome of human hepatocytes.
Int J Mol Sci. 2017;18:E359.
39. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg
effect: the metabolic requirements of cell proliferation. Science. 2009;324:
1029–33.
40. Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, et al.
Increased lactate secretion by cancer cells sustains non-cell-autonomous
adaptive resistance to MET and EGFR targeted therapies. Cell Metab. 2018;
28:848–65.
41. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation
and progression. Nature. 2004;432:332–7.
42. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments
in solid tumors: new targets for therapy. Genes Dev. 2011;25:2559–72.
43. Lussey-Lepoutre C, Hollinshead KE, Ludwig C, Menara M, Morin A, Castro-
Vega LJ, et al. Loss of succinate dehydrogenase activity results in
dependency on pyruvate carboxylation for cellular anabolism. Nat
Commun. 2015;6:8784.
44. Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in
Cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169–80.
45. Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer
cells? Cell Cycle. 2010;9:3884–6.
46. Dang CV. Rethinking the Warburg effect with Myc micromanaging
glutamine metabolism. Cancer Res. 2010;70:859–62.
47. Tripathi P, Kamarajan P, Somashekar BS, MacKinnon N, Chinnaiyan AM,
Kapila YL, et al. Delineating metabolic signatures of head and neck
squamous cell carcinoma: phospholipase A2, a potential therapeutic target.
Int J Biochem Cell Biol. 2012;44:1852–61.
48. Maus A, Peters GJ. Glutamate and alpha-ketoglutarate: key players in glioma
metabolism. Amino Acids. 2017;49:21–32.
49. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis
at the cellular and whole-body levels. Annu Rev Nutr. 2014;34:31–55.
50. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to
target therapeutic agents to the central nervous system and treat
neurodegenerative disease. BMC Neurosci. 2008;9(Suppl 3):S5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
D’Alessandro et al. Cell Communication and Signaling          (2019) 17:108 Page 12 of 12
